Arcturus Therapeutics Holdings Inc. (ARCT) Stock Grade

About Arcturus Therapeutics Holdings Inc.'s fundamentals

Arcturus Therapeutics is a small-cap biotech company with a market capitalization of $167.9 million that reported a significant net loss in its latest annual statement, reflected in a net margin of -97.9%. The company experienced a steep 51.4% decline in revenue year-over-year, indicating substantial contraction in its business performance. As a loss-making biotech firm, traditional valuation metrics like P/E ratio and return on equity are not applicable, and the company does not pay a dividend.